Posteligeo 20mg, a rare two-type non-Hodgkin lymphoma treatment of Kyowa Hakogirin, is expected to be approved. It has been four years since the U.S. Food and Drug Administration (FDA) approved the treatment of mycosis fungoids (MF) or Sézary syndrome (SS) in August 2018. According to the pharmaceutical industry on the 26th, the Ministry of Food and Drug Safety recently completed Potseligeo's safety and efficacy review. It has been four years since the U.S. Food and Drug Administration (FDA) approved the treatment of mycosis fungoids (MF) or Sézary syndrome (SS) in August 2018. According to the pharmaceutical industry on the 26th, the Ministry of Food and Drug Safety recently completed Posteligeo's safety an